Maully J. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maully J. Shah has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
Anne Foster
Advocate Children's Heart Institute, Chicago, Illinois
6 shared publications- Anne M. Dubin
Division of Pediatric Cardiology, Lucile Packard Children’s Hospital, Stanford University, Palo Alto, CA (A.M.D.).
6 shared publications Brynn E. Dechert
University of Michigan, Ann Arbor, Michigan
6 shared publicationsFrank Cecchin
New York University Grossman School of Medicine, New York, New York
6 shared publicationsJohn Triedman
Harvard Medical School, Boston, Massachusetts
6 shared publicationsSeshadri Balaji
Oregon Health & Science University, Portland, Oregon
6 shared publications
Latest Publications
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (3) , e014288
Shocking Practices of Pediatric Electrophysiologists: Contemporary Defibrillation Testing Data From a Multicenter National CIED Registry
- 1 March 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (3) , e014288
Shocking Practices of Pediatric Electrophysiologists: Contemporary Defibrillation Testing Data From a Multicenter National CIED Registry
- 2 January 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (1) , 223-224
Top stories: Pediatric CIEDs
- 2 January 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (1) , 223-224
Top stories: Pediatric CIEDs
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014424
Safety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial
BACKGROUND: The LEADR (Lead Evaluation for Defibrillation and Reliability) trial evaluated the small-diameter (4.7F), lumenless, integrated bipolar OmniaSecure defibrillation lead. The trial exceeded primary safety and efficacy objective thresholds, demonstrating favorable efficacy at implant and a low rate of complications. Three-year term outcomes of the LEADR trial assessing the OmniaSecure lead are reported here. METHODS: The LEADR trial is a prospective, multicenter, single-arm clinical trial. Patients with an indication for de novo implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator were implanted with the OmniaSecure lead in standard right ventricle locations and followed at prespecified intervals. The lead was evaluated for safety, efficacy, and reliability through final follow-up. RESULTS: There were 643/657 patients (97.9%) successfully implanted with the OmniaSecure lead with a mean follow-up of 32.4±9.1 months (26% female, 61.9±12.9 years). Pacing capture threshold, pacing impedance, and R-wave amplitudes remained stable throughout. There was a 96.5% freedom from major study lead-related complications at 3 years. At 3 years, 22.3% of patients received appropriate therapies, that is, shock and antitachycardia pacing, with a 75.4% antitachycardia pacing efficacy. Inappropriate shock rate was 2.7% and 5.9% at 1 and 3 years, respectively. CONCLUSIONS: The final results of the LEADR trial demonstrated 3-year term safety, efficacy, and reliability of the OmniaSecure lead, emphasizing the potential utility of this lead in a wide variety of patients.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014424
Open AccessSafety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial
BACKGROUND: The LEADR (Lead Evaluation for Defibrillation and Reliability) trial evaluated the small-diameter (4.7F), lumenless, integrated bipolar OmniaSecure defibrillation lead. The trial exceeded primary safety and efficacy objective thresholds, demonstrating favorable efficacy at implant and a low rate of complications. Three-year term outcomes of the LEADR trial assessing the OmniaSecure lead are reported here. METHODS: The LEADR trial is a prospective, multicenter, single-arm clinical trial. Patients with an indication for de novo implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator were implanted with the OmniaSecure lead in standard right ventricle locations and followed at prespecified intervals. The lead was evaluated for safety, efficacy, and reliability through final follow-up. RESULTS: There were 643/657 patients (97.9%) successfully implanted with the OmniaSecure lead with a mean follow-up of 32.4±9.1 months (26% female, 61.9±12.9 years). Pacing capture threshold, pacing impedance, and R-wave amplitudes remained stable throughout. There was a 96.5% freedom from major study lead-related complications at 3 years. At 3 years, 22.3% of patients received appropriate therapies, that is, shock and antitachycardia pacing, with a 75.4% antitachycardia pacing efficacy. Inappropriate shock rate was 2.7% and 5.9% at 1 and 3 years, respectively. CONCLUSIONS: The final results of the LEADR trial demonstrated 3-year term safety, efficacy, and reliability of the OmniaSecure lead, emphasizing the potential utility of this lead in a wide variety of patients.
- 4 December 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (1) , 41-43
Slow Conducting Anatomical Isthmus and VT Inducibility in Repaired Tetralogy of Fallot
- 4 December 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (1) , 41-43
Slow Conducting Anatomical Isthmus and VT Inducibility in Repaired Tetralogy of Fallot
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (12) , e013600
Predictors of Response to Cardiac Resynchronization Therapy in Pediatric Patients and Patients With Congenital Heart Disease
BACKGROUND: Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric patients and patients with congenital heart disease with reduced systemic ventricular ejection fraction (SVEF). However, the identification of optimal responders is challenging. This study aimed to identify predictors of response to CRT in children and patients with congenital heart disease at 5 large quaternary referral centers. METHODS: Patients were aged P =0.013), biventricular circulation ( P =0.022), systemic left ventricle ( P =0.021), and conduction delay to the lateral wall of the systemic ventricle ( P =0.01) were associated with a positive response. For the assessment of the secondary outcome, 324 controls were identified. Median follow-up is 5.1 (interquartile range, 2.0–8.6) years. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic right ventricle ( P =0.69) or without prior single-site pacemaker ( P =0.20). CONCLUSIONS: CRT in children and patients with congenital heart disease frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to the lateral wall of the systemic ventricle, and those with a systemic left ventricle are most likely to respond.
- 1 December 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (12) , e013600
Predictors of Response to Cardiac Resynchronization Therapy in Pediatric Patients and Patients With Congenital Heart Disease
BACKGROUND: Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric patients and patients with congenital heart disease with reduced systemic ventricular ejection fraction (SVEF). However, the identification of optimal responders is challenging. This study aimed to identify predictors of response to CRT in children and patients with congenital heart disease at 5 large quaternary referral centers. METHODS: Patients were aged P =0.013), biventricular circulation ( P =0.022), systemic left ventricle ( P =0.021), and conduction delay to the lateral wall of the systemic ventricle ( P =0.01) were associated with a positive response. For the assessment of the secondary outcome, 324 controls were identified. Median follow-up is 5.1 (interquartile range, 2.0–8.6) years. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic right ventricle ( P =0.69) or without prior single-site pacemaker ( P =0.20). CONCLUSIONS: CRT in children and patients with congenital heart disease frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to the lateral wall of the systemic ventricle, and those with a systemic left ventricle are most likely to respond.
- 23 September 2025
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 17 (4)
Complex Arrhythmias in Pediatrics and Congenital Heart Disease: Case Review
- 23 September 2025
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 17 (4)
Complex Arrhythmias in Pediatrics and Congenital Heart Disease: Case Review
- Open Access
Predictors of Response to Cardiac Resynchronization Therapy in Pediatric and Congenital Heart Disease Patients
Background: Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging. Objective: To identify predictors of response to CRT in children and CHD patients at 5 large quaternary referral centers. Methods: Patients were <21 years or had CHD; had SVEF <45%; symptomatic heart failure; and significant electrical dyssynchrony prior to CRT. Primary outcome was defined as an ordinal response at 6/12months: (1) Improved EF [≥5%], (2) Unchanged SVEF, (3) Worse SVEF. Secondary outcome utilized a propensity score-matched control cohort. Response to CRT was defined using longitudinal trajectory of SVEF up to latest follow-up. Results: In total, 167 eligible CRT recipients were identified across the 5 centers. 150 had comprehensive data at 6/12months: 96(64%) with improved SVEF, 26(17%) unchanged, 28(19%) worsened. Mean increase in SVEF was 11% [IQR 3-21%]. On univariable ordinal regression, lower SVEF (p=0.013), biventricular circulation (p=0.022), systemic LV (p=0.021), and conduction delay to lateral wall of SV (p=0.01) were associated with positive response. For assessment of secondary outcome, 324 controls were identified. Mean follow-up 4.2(±3.7) yrs. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic RV (p=0.69) or without prior single site pacemaker (p=0.20). Conclusion: CRT in children and CHD patients frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to lateral wall of the SV and those with systemic LV are most likely to respond. Condensed Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging. In this multicenter study, pediatric and CHD CRT recipients with heart failure and EF<45% were identified. The primary outcome was change in EF at 6/12months. Those with lower baseline SVEF, conduction delay to lateral wall of the SV and/or systemic LV were most likely to respond to CRT. When compared to propensity score-matched controls, the CRT groups also demonstrated a significantly better long-term EF trajectory.
Open AccessPredictors of Response to Cardiac Resynchronization Therapy in Pediatric and Congenital Heart Disease Patients
Background: Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging. Objective: To identify predictors of response to CRT in children and CHD patients at 5 large quaternary referral centers. Methods: Patients were <21 years or had CHD; had SVEF <45%; symptomatic heart failure; and significant electrical dyssynchrony prior to CRT. Primary outcome was defined as an ordinal response at 6/12months: (1) Improved EF [≥5%], (2) Unchanged SVEF, (3) Worse SVEF. Secondary outcome utilized a propensity score-matched control cohort. Response to CRT was defined using longitudinal trajectory of SVEF up to latest follow-up. Results: In total, 167 eligible CRT recipients were identified across the 5 centers. 150 had comprehensive data at 6/12months: 96(64%) with improved SVEF, 26(17%) unchanged, 28(19%) worsened. Mean increase in SVEF was 11% [IQR 3-21%]. On univariable ordinal regression, lower SVEF (p=0.013), biventricular circulation (p=0.022), systemic LV (p=0.021), and conduction delay to lateral wall of SV (p=0.01) were associated with positive response. For assessment of secondary outcome, 324 controls were identified. Mean follow-up 4.2(±3.7) yrs. Almost all subgroups demonstrated improved SVEF trend with CRT, except those with systemic RV (p=0.69) or without prior single site pacemaker (p=0.20). Conclusion: CRT in children and CHD patients frequently results in an improvement in SVEF. Those with lower SVEF, conduction delay to lateral wall of the SV and those with systemic LV are most likely to respond. Condensed Cardiac resynchronization therapy (CRT) is an important therapeutic option in selected pediatric and congenital heart disease (CHD) patients with reduced systemic ventricular (SV) ejection fraction (EF). However, the identification of optimal responders is challenging. In this multicenter study, pediatric and CHD CRT recipients with heart failure and EF<45% were identified. The primary outcome was change in EF at 6/12months. Those with lower baseline SVEF, conduction delay to lateral wall of the SV and/or systemic LV were most likely to respond to CRT. When compared to propensity score-matched controls, the CRT groups also demonstrated a significantly better long-term EF trajectory.
- 13 August 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (7) , 516-530
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.
- 13 August 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (7) , 516-530
Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study
BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.
- 4 September 2023
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 15 (4)
Advances in Cardiac Implantable Electronic Devices and Congenital Heart Disease
- 4 September 2023
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 15 (4)
Advances in Cardiac Implantable Electronic Devices and Congenital Heart Disease
- 5 August 2023
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 15 (4) , 421-432
Leadless Pacemakers in Patients with Congenital Heart Disease
- 5 August 2023
- Published by Elsevier in Cardiac Electrophysiology Clinics
- Vol. 15 (4) , 421-432
Leadless Pacemakers in Patients with Congenital Heart Disease